A further thought and a question.
The next 18 months are likely to be expensive. The Prostact trial is unlikey to be cheap, and it's unclear at the moment how long it will take for Illucix to grow into its share of the higher TAM (or what that share will be). There are also further royalty payments, so I expect expenses to rise with income for 2024. That's not a complaint, if they get therapy to market it will be worth it.
The question- and yes it's a dumb one- presumably they'll be using Illucix to monitor disease progression in the Prostact trials, including the Prostact Select that was recently (partially) reported. So if the therapy's effective presumably there'll be images to back that up eventually?
CB presenting at Jefferies London this Thursday (3am), page-11
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.13 |
Change
-0.340(1.75%) |
Mkt cap ! $6.401B | |||
| Open | High | Low | Value | Volume |
| $19.41 | $19.46 | $18.81 | $121.0M | 6.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7316 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.13 | 6814 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |